Shenzhen Hepalink Pharma Invests $22 Million in TPG Biotech Fund

Shenzhen Hepalink Pharma, a heparin API company, will invest $22 million in the TPG Biotechnology Partners IV fund. TPG (formerly Texas Pacific Group) is a global venture capital company that invests in all types of life sciences companies at all stages of their development. The firm says it has made $1 billion of investments in 50 life science companies since 2002. More details.... Stock Symbol: (SHE: 002399) Share this with colleagues: // //